Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 31Neoplasms 8Endometrial Neoplasms 6Neoplasm Metastasis 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Meningioma 3Glioblastoma 3Sarcoma 2Pancreatic Neoplasms 2Oligodendroglioma 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Recurrence 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasm, Residual 1Multiple Myeloma 1

Interventions

Temozolomide 5Radiotherapy 2Bevacizumab 2tozuleristide 1olutasidenib 1abemaciclib 1Radiation 1Nivolumab 1Megestrol Acetate 1Lomustine 1Lapatinib 1Irinotecan 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Disulfides 1Cyproheptadine 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Spinal Cord Neoplasms × abemaciclib × Clear all
NCT06413706 2026-05-22

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Eli Lilly and Company

Phase 2 Active not recruiting
45 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡